Search
Beigene Ltd
ONCAdd to Watchlist
309.925USD
-5.145-1.63%
Market hours （ET）Quotes delayed by 15 min
31.69BMarket Cap
66.39P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.63%
5 Days
+4.18%
1 Month
+0.09%
6 Months
-17.89%
Year to Date
+2.01%
1 Year
+32.87%
TradingKey Stock Score of Beigene Ltd
Currency: USD Updated: 2026-05-12Key Insights
Beigene Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 10 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 405.33.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beigene Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Beigene Ltd Highlights
StrengthsRisks
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 5.34B.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 117.30% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 67.49, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 40.42M shares, increasing 4.63% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 1.51K shares of this stock.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
405.335
Target Price
+29.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Beigene Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Beigene Ltd Info
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Ticker SymbolONC
CompanyBeigene Ltd
CEOOyler (John Victor)
Websitehttps://beonemedicines.com/
Related Instruments
+1.62%
+0.88%
+2.12%
+0.05%
+1.35%
+1.17%
-0.01%
-0.74%
+0.11%
+0.46%
+0.32%
+0.83%
+0.23%
+0.49%
+1.31%
+0.69%
0.00%
+0.43%
-1.55%
-0.09%Popular Instruments
100.532
+1.233 (+1.24%)
295.980
+1.180 (+0.40%)
224.190
+3.410 (+1.54%)
4681.090
-48.030 (-1.02%)
485.490
-3.250 (-0.66%)
1445.470
-6.550 (-0.45%)
795.481
+28.901 (+3.77%)
390.700
+3.350 (+0.86%)
79698.000
-968.870 (-1.20%)
433.387
-0.063 (-0.01%)
